← All approvals · Cancer · 2026
Veppanu (vepdegestrant)
The FDA approved Veppanu (vepdegestrant) on May 1, 2026 to treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
- Brand name
- Veppanu
- Generic name
- vepdegestrant
- FDA approval date
- May 1, 2026
- Approved use (FDA wording)
- To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
- Company
- Rigel Pharms
- Application
- NDA219835
- Dosage form / route
- TABLET · ORAL
- Boxed warning on label
- Not listed
- Category on this site
- Cancer
Indications and usage, from the FDA label
VEPPANU is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1) -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. VEPPANU is a heterobifunctional protein degrader indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 ( ESR1) -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine ther…